Dr. Eric K. Seaman is the founder and director of the Center for Vasectomy, Vasectomy Reversal and Male Fertility in Millburn, New Jersey. A urologist certified by the American Board of Urology specializing in microsurgery, Dr. Seaman is one of the leading practitioners of Male Reproductive Medicine in the New Jersey and New York Metro region. Dr. Seaman has focused his practice on the sub-specialty of Male Reproductive Medicine and Surgery. Dr. Seaman is also trained in microsurgical techniques for vasectomy reversals, varicocelectomy and surgical sperm retrieval techniques. Dr. Seaman has performed over 1,000 vasectomies and practices no scalpel, and no needle techniques. For the fourth year, Dr. Seaman has been recognized as one of New Jersey’s “Top Doctors” by New Jersey Monthly Magazine. This recognition is based on ballots cast by other physicians regarding whom they would recommend to their patients.
A native of Hewlett, Long Island, Dr. Seaman graduated Summa Cum Laude and Phi Beta Kappa from University of Pennsylvania, and Alpha Omega Alpha from New York University (NYU) Medical School. He completed his Urology Residency at Columbia Presbyterian Medical Center in 1995 and went on to complete a Fellowship in Male Reproductive Medicine and Surgery at Baylor College of Medicine, Houston, in 1996. Dr. Seaman also graduated Beta Gamma Sigma from Rutgers University Business School’s Executive MBA program (class of 2006).
A staunch advocate of high professional standards, Dr. Seaman led the successful effort to form Urology Group of New Jersey (UGNJ), serving as its president from the organization’s founding in 2008 to January 2012.
Dr. Seaman created the Center for Vasectomy, Vasectomy Reversal and Male Fertility to provide widespread access to advanced male reproductive health care services and is proud and delighted at the positive change he has helped bring to the lives of so many of the Center’s patients.
Dr. Eric Seaman has focused his New Jersey Urology practice on Male Reproductive Medicine and Surgery since 1996. As part of his focus, he has received special training on vasectomy reversal and specializes in complex microsurgical procedures for male fertility.
Dr. Seaman has privileges at Saint Barnabas, Newark Beth Israel, Morristown Memorial and East Orange general Medical Centers. He completed his medical degree in 1989 at New York University School of Medicine and Urology Residency at the Columbia Presbyterian Colleges of Physicians and Surgeons in New York. Subsequent to that he completed a clinical fellowship in Male Reproductive Medicine and Surgery at Baylor College of Medicine in Houston Texas during which time he frequently participated in two or three reversal procedures a week. He has also completed animal research work on vasectomy reversal.
Dr. Seaman’s practice for the past 18 years has specialized in fertility related services. He is an experienced micro-surgeon having performed over 1500 microsurgical procedures including vasectomy reversal, microsurgical varicocelectomy and microsurgical testicular sperm extraction. He is also one of the few New Jersey Urologists to offer the no-needle, no-scalpel vasectomy procedure.
Dr. Seaman is certified by the American Board of Urology. He is a fellow of the American College of Surgeons. He has been selected as “top Doctor” by New Jersey Monthly for the past several years.
The office of Dr. Eric Seaman has become the first site in New Jersey for a new test for male fertility called a “CAP-score” made by the privately held company, Androvia.
The limitations of the predictive ability of a semen analysis are well recognized since the test literally relies on “looking” at sperm. Semen analysis relies on measurements of count, motility and shape a proxies for fertilizing ability. But those aren’t actually tests of sperm function at all.
The Androvia test is a readily performed measure of the “capacitation” ability of the sperm. “Capacitation” refers to maturational changes a sperm MUST undergo in order to penetrate and fertilize an egg.
Dr. Seaman’s office was involved with some of Androvia’s initial research and aided in their ability to define CAP-score results for a normal vs. an infertile population. Initially the test will be offered at a significantly discounted fee for the first 50 specimen and tests are currently limited to 2 specimens a week and only on Thursdays. People who are interested must be a patient of Dr. Seaman’s. The test cannot be performed on patients with a severely low sperm count or density below 3Million/ml. It is hoped that new technology such as the cap score can offer new guidance in couples with male factor infertility. For more information visit http://www.androvialifesciences.com/cap-score-sperm-function-test.